Ageing biology moved from a fringe academic interest to a funded biotech sector in under a decade. This page maps that sector using the LongevityHub Pro database — which segments are crowded, which are still preclinical, where the capital is going, and which countries are building the companies.
Figures below are a snapshot of our tracked dataset as of . They describe what we index, not the entire market.
Companies are grouped by the primary mechanism their lead programme targets. Counts reflect a company's declared primary focus area, so a platform business with a senolytic asset appears once, under platform.
Discovery engines, AI-driven target identification, ageing-clock software and funds. Sells into the rest of the field rather than to patients, so revenue arrives earlier than clinical proof.
Tracked examples: Recursion Pharmaceuticals, Gerostate Alpha, Spring Discovery, Gero AI, Novos Labs, VitaDAO
Companies whose lead programmes address a hallmark of ageing directly, usually with a disease indication attached for regulatory purposes.
Tracked examples: Alector, Maze Therapeutics, Kronos Bio, Biosplice Therapeutics, Deep Genomics, Variant Bio
Epigenetic clocks, multi-omic panels and functional assays. The commercial bright spot of the field, and the layer any ageing trial ultimately depends on for endpoints.
Tracked examples: Deep Longevity, EpiAge, AgeMeter, Veritas Genetics, Biomarker Labs, Elevage Medical
Clearing or reprogramming senescent cells. Strong preclinical rationale; the clinical record so far is mixed and highly tissue-dependent.
Tracked examples: Aclaris Therapeutics, Marble Therapeutics, Geros Senotherapeutics, Senolytx Therapeutics, Nuvation Bio, Vor Biopharma
NAD+ precursors, mitochondrial and mTOR-adjacent metabolic programmes. Split between consumer supplement economics and genuine drug development.
Tracked examples: Navitor Pharmaceuticals, Mitobridge (AbbVie Subsidiary), Iduna Therapeutics, Qualia Life Sciences, Mthera Pharma, Timeline Nutrition
Modulating the epigenome to restore youthful gene expression, plus the measurement tooling that makes such claims testable.
Tracked examples: Eterna Therapeutics, EpiBeat Therapeutics, Amplitude Therapeutics, Longevica Pharmaceuticals
Autologous and allogeneic cell products aimed at regenerating exhausted tissue compartments — kidney, immune system, cartilage.
Tracked examples: ProKidney, Cellino Biotech, ImmunAge Biotech, Seachange Bio
Plasma-fraction, xenotransplant and systemic-factor approaches. Scientifically bold, and the sub-segment where evidence quality varies most.
Tracked examples: Alkahest, eGenesis, Centauri Therapeutics, Young Blood Institute
Transient expression of pluripotency factors or equivalent to reset cellular age without losing cell identity. Almost entirely preclinical.
Tracked examples: Tome Biosciences, Exsilio Therapeutics, Kriya Therapeutics, Minicircle
Delivering longevity-associated genes (telomerase, follistatin, Klotho variants) via viral and non-viral vectors.
Tracked examples: Genflow Biosciences, Geron Corporation, BioViva Science
Removing accumulated molecular damage — crosslinks, aggregates, lipofuscin — that no existing clearance pathway handles well.
Tracked examples: Revel Pharmaceuticals, Underdog Pharmaceuticals, Fortify Biosystems
High-plex protein measurement, now the main engine behind proteomic ageing clocks and organ-specific age estimates.
Tracked examples: SomaLogic, Olink Proteomics, Seer Bio
This is the single most important sanity check on the sector. Preclinical companies outnumber every clinical stage combined by roughly four to one, and only four tracked companies have a Phase 3 asset. The commercial tier — diagnostics, clinics, consumer products — is where most of today's revenue sits.
The United States holds about 65% of tracked companies, concentrated in the Bay Area, Boston and San Diego. Switzerland punches far above its population thanks to Basel's pharma cluster and a favourable clinic regime, while the UK's cohort skews towards academic spinouts from Cambridge, Oxford and London.
The remaining 24 countries each contribute fewer than four tracked companies, led by Japan, the Netherlands and the UAE.
Eight of the largest rounds logged in mid-2026. Two patterns stand out: preventive diagnostics and clinic-style consumer health attract the biggest cheques, while mechanism-first therapeutics raise structured Series A and B rounds backed by corporate venture arms.
| Company | Amount | Round | Date | Lead investors |
|---|---|---|---|---|
| Neko Health | $700M | Series C | 2026-07-15 | Lightspeed (lead), O.G. Venture Partners, Atomico, General Catalyst, Lakestar |
| SonoThera | $125M | Series B | 2026-06-10 | Vida Ventures, ARK Invest, Leaps by Bayer, ARCH Venture Partners, J&J Innovation |
| COUR Pharmaceuticals | $50M | Series B | 2026-06-18 | Lumira Ventures, Roche Venture Fund, Sanofi, Pfizer Ventures, Angelini Ventures |
| Enhanced Group | $50M | Series A | 2026-06-28 | Not disclosed |
| Everlab | AU$65M | Series A | 2026-06-16 | Airtree Ventures, Plural, Left Lane Capital, b2venture |
| Rapalogix Health | $20M | Series A | 2026-06-23 | Not disclosed |
| Rem3dy Health | $18.5M | Series A | 2026-06-28 | Not disclosed |
| Gero | $17M | Series A | 2026-06-17 | Melnichek Investments |
Regulators do not approve drugs for ageing. Every credible programme therefore pairs a geroscience mechanism with a measurable indication — frailty, sarcopenia, osteoarthritis, fibrosis, ocular or neurodegenerative disease. Companies that cannot name their indication and endpoint are still science projects.
The 19 tracked diagnostics companies are effectively building the measuring stick the rest of the field needs. Until an ageing biomarker is accepted as a surrogate endpoint, trial timelines stay long and expensive.
A single 2026 round — Neko Health's $700M — exceeds the combined total of the next several we logged. Headline sector totals are dominated by a handful of consumer and diagnostics deals, which flatters therapeutic funding if read carelessly.
With 194 commercial-stage companies selling tests, supplements, software and clinic services into overlapping audiences, differentiation is thin. Expect acquisitions and closures well before the therapeutic pipeline matures.
Biotechnology aging research applies biotech tools — gene therapy, cell therapy, small molecules, epigenetic reprogramming and multi-omic diagnostics — to the biological processes that drive ageing rather than to a single age-related disease. Most programmes target one or more of the hallmarks of ageing, such as cellular senescence, mitochondrial dysfunction, impaired autophagy, stem-cell exhaustion or epigenetic drift.
LongevityHub Pro currently tracks 595 companies across 34 countries, from preclinical startups to publicly listed biotechs. The count grows every week as new entities are indexed, so the platform figure is a floor rather than a definitive market census.
The United States accounts for 387 of the 595 companies tracked (about 65%). Switzerland (40) and the United Kingdom (38) follow, with Germany, Australia, Singapore and Canada forming the next tier.
Mostly early. Of the companies tracked, 250 are preclinical, 22 are in Phase 1, 19 in Phase 2 and 4 in Phase 3. A further 194 are commercial (diagnostics, supplements, clinics, software) and 80 are publicly listed. That mix explains why validated clinical endpoints remain the field's central bottleneck.
Not today. Regulators approve therapies against specific indications, so ageing-focused companies run trials in concrete diseases or functional endpoints — frailty, sarcopenia, osteoarthritis, fibrosis, neurodegeneration — and treat geroscience as the mechanism rather than the label.
The full company profiles, funding history, trial records and research digest behind this page live inside LongevityHub Pro, updated daily.